Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
$10.00
+3.0%
$8.10
$5.01
$18.71
$59.61M0.18116,804 shs112,201 shs
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
$6.25
+10.4%
$4.46
$3.39
$16.00
$67.69M0.7768,835 shs800,947 shs
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
$0.20
$0.17
$2.96
$13M-25.84N/AN/A
Renovaro Inc. stock logo
RENB
Renovaro
$0.32
+0.6%
$0.32
$0.26
$2.10
$54.55M0.511.60 million shs831,375 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
+4.63%+2.43%+24.49%+57.37%-19.42%
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
+16.70%+15.51%+26.62%+28.34%-56.40%
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
0.00%0.00%0.00%0.00%-56.53%
Renovaro Inc. stock logo
RENB
Renovaro
-7.05%+6.02%-12.35%-10.64%-78.12%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
4.4046 of 5 stars
3.43.00.04.72.62.50.6
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
3.0237 of 5 stars
3.53.00.00.02.21.71.3
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
N/AN/AN/AN/AN/AN/AN/AN/A
Renovaro Inc. stock logo
RENB
Renovaro
2.2354 of 5 stars
0.05.00.00.02.53.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
2.83
Moderate Buy$20.00100.00% Upside
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
3.00
Buy$30.00380.00% Upside
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
0.00
N/AN/AN/A
Renovaro Inc. stock logo
RENB
Renovaro
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest CHHE, AVTX, RENB, and ATRA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/2/2025
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$15.00
(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
$199.73M0.30N/AN/A($16.89) per share-0.59
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
$440K153.84N/AN/A$12.80 per share0.49
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
$110K0.00N/A47.17N/ANaN
Renovaro Inc. stock logo
RENB
Renovaro
N/AN/AN/AN/A$0.89 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
-$85.40M-$3.72N/AN/AN/A-7.83%N/A-14.51%8/11/2025 (Estimated)
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
-$35.13MN/A0.00N/AN/AN/A111.00%58.88%8/11/2025 (Estimated)
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
-$410K-$0.020.00N/AN/AN/AN/AN/AN/A
Renovaro Inc. stock logo
RENB
Renovaro
-$88.43M-$0.77N/AN/AN/A-60.38%-47.04%9/29/2025 (Estimated)

Latest CHHE, AVTX, RENB, and ATRA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2025Q2 2025
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
-$0.32N/AN/AN/A$4.23 millionN/A
8/11/2025Q2 2025
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
-$1.43N/AN/AN/AN/AN/A
5/15/2025Q1 2025
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
-$3.07$3.50+$6.57$3.50$4.30 million$98.10 million
5/12/2025Q1 2025
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
-$1.07-$1.25-$0.18-$1.25N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
N/AN/AN/AN/AN/A
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
N/AN/AN/AN/AN/A
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
N/AN/AN/AN/AN/A
Renovaro Inc. stock logo
RENB
Renovaro
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
N/A
0.57
0.57
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
N/A
22.61
22.61
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
N/AN/AN/A
Renovaro Inc. stock logo
RENB
Renovaro
N/A
0.13
0.13

Institutional Ownership

CompanyInstitutional Ownership
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
70.90%
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
87.06%
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
N/A
Renovaro Inc. stock logo
RENB
Renovaro
71.41%

Insider Ownership

CompanyInsider Ownership
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
4.00%
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
3.03%
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
31.30%
Renovaro Inc. stock logo
RENB
Renovaro
21.72%
CompanyEmployeesShares OutstandingFree FloatOptionable
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
3305.96 million5.72 millionOptionable
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
4010.83 million10.50 millionNot Optionable
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
4064.95 million44.62 millionNot Optionable
Renovaro Inc. stock logo
RENB
Renovaro
20172.12 million134.74 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Atara Biotherapeutics stock logo

Atara Biotherapeutics NASDAQ:ATRA

$10.00 +0.29 (+2.99%)
Closing price 04:00 PM Eastern
Extended Trading
$10.30 +0.30 (+3.00%)
As of 06:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Avalo Therapeutics stock logo

Avalo Therapeutics NASDAQ:AVTX

$6.25 +0.59 (+10.42%)
Closing price 04:00 PM Eastern
Extended Trading
$6.37 +0.12 (+1.92%)
As of 06:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

China Health Industries stock logo

China Health Industries OTCMKTS:CHHE

China Health Industries Holdings, Inc., through its subsidiaries, manufactures and sells health products. The company operates through three segments: Humankind, HLJ Huimeijia, and Others. The company offers hemp derivative products, such as hemp oil, hemp protein powder, hemp polypeptides, collagen peptides, hemp essence repair lotions, hemp revitalizing essence products, hemp anti-aging brightening eye creams, hemp frozen age nourishing creams, hemp seed beers, and hemp seeds. It also provides health supplements, including Sailuozhi soft capsule, which is made from frog oil, soybean isoflavone, procyanidine, and vitamin E for freckle removal and skin moisture supplements under the QunLe brand; and propolis and black ant capsule that is made from propolis, black ant, acanthopanax, and astragalus root under the Kindlink brand. In addition, the company offers health products for acne removal, relieving eyestrain, enhancing bone density, enhancing memory, enhancing nutritional anemia and chloasma, relaxing bowels and promoting the discharge of lead, enhancing immunity and relieving physical fatigue, and dispelling chloasma, as well as iron and multivitamin, and mineral supplements. Further, it manufactures and sells various types of medical drugs, such as enema glycerini, umguentumacidi borici camphoratum, ge hong beriberi water, pelvic inflammation suppository, injury and paralysis tincture, indometacin and furazolidone suppositories, injury and rheumatism relieving paste, refining goupi cream, muskiness pain relieving paste, muskiness bone strengthener paste, matrine suppositories, ethacriding lactate solution, iodine tincture, mercurochrome solution, hydrogen peroxide solution, halcinonide cream, compound fluocinonide tincture, and policresulen vaginal suppository. The company primarily sells its products through sales personnel and sales agents. China Health Industries Holdings, Inc. was founded in 1996 and is based in Harbin City, the People's Republic of China.

Renovaro stock logo

Renovaro NASDAQ:RENB

$0.32 +0.00 (+0.57%)
Closing price 04:00 PM Eastern
Extended Trading
$0.31 0.00 (-1.23%)
As of 06:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.